KRT6A and melanoma: PDIA3 has been recentlysuggested as a robust prognostic biomarker for pan-cancers and couldsignificantly predict anti-PDL1 therapy response.40 Keratins KRT6A and KRT17 have also been suggested as potentialprognostic biomarkers for melanoma due to their role in cancer cellproliferation, immune cell infiltration and metastasis.41 In conclusion, the findings suggest that EVsprovide unique additional proteomics information that cannot be obtainedfrom plasma alone and that proteins of EV origin form an integralpart of the plasma proteome.